Alcon's new surgical platforms and lenses are gaining adoption, and dry eye momentum is expected to support growth, but adverse macroeconomic conditions and intense competition remain concerns. The company reported share gains in U.S. AT-IOLs and is preparing to launch an upgraded Vivity lens in early 2027, while continuing to scale Tryptyr and Systane in dry eye and broaden its contact lens lineup with TOTAL30 and PRECISION7. However, incremental tariffs in the United States and China totaled $33 million in the first quarter of 2026, creating a 120 basis points drag on core gross margin, and competition is intensifying outside the United States. The Zacks Consensus Estimate for 2026 earnings per share has remained unchanged at $3.48 over the past 30 days, with revenues pegged at $11.06 billion, suggesting a 7.2% rise from the prior year. Alcon stock has dipped 25.1% over the past year, compared with a 10.4% decline for the industry and a 23.9% rise for the S&P 500.
Alcon AGIncremental tariffs in the US and China created a $33 million drag and 120 bps hit to core gross margin.
LENSAR Inc
Advanced Micro Devices Inc
Globus Medical
Integra LifeSciences Holdings
Phibro Animal Health Corporation